CANSOUL has made a strategic equity investment in SYNBIOTIC SE to leverage synergies and support growth in the medical cannabis and industrial hemp sectors.

Target Information

SYNBIOTIC SE, based in Düsseldorf, is a notable European enterprise specializing in the medical cannabis and industrial hemp sectors. The company is publicly traded and operates on a buy-and-build investment strategy aimed at enhancing its footprint across Europe. SYNBIOTIC’s business model encompasses a comprehensive value chain that includes cultivation, production, research, and retail, focusing on the development and commercialization of medical cannabis, CBD products, and industrial hemp.

The company has robust assets, including an import license and Good Manufacturing Practice (GMP) certification for medical cannabis. SYNBIOTIC also holds a share in GOC Nexus, which utilizes a patented cold plasma technology for GMP sterilization, providing the company with a significant competitive edge in quality enhancement.

Industry Overview

The cannabis industry in Germany is experiencing transformative growth, driven by increasing public acceptance and regulatory developments. Although there are expectations surrounding the potential for recreational use, experts assert that commercial recreational cannab